M Beatrice Bilò1, Leonardo Antonicelli, Floriano Bonifazi. 1. Department of Internal Medicine, Immunology, Allergy and Respiratory Diseases, University Hospital, Ancona, Italy. b.bilo@ospedaliriuniti.marche.it
Abstract
PURPOSE OF REVIEW: Although highly effective, venom immunotherapy (VIT) may be responsible for local and systemic allergic reactions. There is a good theoretical basis for believing that purified aqueous and purified aluminium hydroxide adsorbed (so-called depot) extracts, commercially available in Europe, have the potential to reduce the incidence of VIT's side effects. The aim of this article is to review the literature on safety and effectiveness of purified preparations as well as compare them with nonpurified extracts. RECENT FINDINGS: Old and new noncomparative studies reveal good tolerance of purified aqueous and purified depot extracts. In comparative trials purified extracts appear to be better tolerated than nonpurified extracts, whereas depot extracts seem to be safer than the corresponding purified aqueous preparation, especially in the prevention of severe large local reactions. The efficacy of purified aqueous and depot extracts is supported by studies using both sting challenge and in-field stings and is comparable to that of nonpurified preparations. SUMMARY: The theoretical basis of the safer profile of purified extracts is supported by a number of clinical studies, making the use of purified depot preparations preferable for conventional treatment also by specialists with less experience in managing VIT. In specialized centres purified aqueous extracts may be preferred for faster build-up protocols. However, further prospective controlled studies are needed in order to evaluate the ability of purified extracts to reduce the frequency of severe systemic reactions over the corresponding nonpurified preparation.
PURPOSE OF REVIEW: Although highly effective, venom immunotherapy (VIT) may be responsible for local and systemic allergic reactions. There is a good theoretical basis for believing that purified aqueous and purified aluminium hydroxide adsorbed (so-called depot) extracts, commercially available in Europe, have the potential to reduce the incidence of VIT's side effects. The aim of this article is to review the literature on safety and effectiveness of purified preparations as well as compare them with nonpurified extracts. RECENT FINDINGS: Old and new noncomparative studies reveal good tolerance of purified aqueous and purified depot extracts. In comparative trials purified extracts appear to be better tolerated than nonpurified extracts, whereas depot extracts seem to be safer than the corresponding purified aqueous preparation, especially in the prevention of severe large local reactions. The efficacy of purified aqueous and depot extracts is supported by studies using both sting challenge and in-field stings and is comparable to that of nonpurified preparations. SUMMARY: The theoretical basis of the safer profile of purified extracts is supported by a number of clinical studies, making the use of purified depot preparations preferable for conventional treatment also by specialists with less experience in managing VIT. In specialized centres purified aqueous extracts may be preferred for faster build-up protocols. However, further prospective controlled studies are needed in order to evaluate the ability of purified extracts to reduce the frequency of severe systemic reactions over the corresponding nonpurified preparation.
Authors: Marek L Kowalski; Ignacio Ansotegui; Werner Aberer; Mona Al-Ahmad; Mubeccel Akdis; Barbara K Ballmer-Weber; Kirsten Beyer; Miguel Blanca; Simon Brown; Chaweewan Bunnag; Arnaldo Capriles Hulett; Mariana Castells; Hiok Hee Chng; Frederic De Blay; Motohiro Ebisawa; Stanley Fineman; David B K Golden; Tari Haahtela; Michael Kaliner; Connie Katelaris; Bee Wah Lee; Joanna Makowska; Ulrich Muller; Joaquim Mullol; John Oppenheimer; Hae-Sim Park; James Parkerson; Giovanni Passalacqua; Ruby Pawankar; Harald Renz; Franziska Rueff; Mario Sanchez-Borges; Joaquin Sastre; Glenis Scadding; Scott Sicherer; Pongsakorn Tantilipikorn; James Tracy; Vera van Kempen; Barbara Bohle; G Walter Canonica; Luis Caraballo; Maximiliano Gomez; Komei Ito; Erika Jensen-Jarolim; Mark Larche; Giovanni Melioli; Lars K Poulsen; Rudolf Valenta; Torsten Zuberbier Journal: World Allergy Organ J Date: 2016-10-12 Impact factor: 4.084
Authors: M Beatrice Bilò; Barbara Cinti; M Feliciana Brianzoni; M Chiara Braschi; Martina Bonifazi; Leonardo Antonicelli Journal: J Allergy (Cairo) Date: 2012-01-12
Authors: Simon Blank; Stefanie Etzold; Ulf Darsow; Maximilian Schiener; Bernadette Eberlein; Dennis Russkamp; Sara Wolf; Anke Graessel; Tilo Biedermann; Markus Ollert; Carsten B Schmidt-Weber Journal: Hum Vaccin Immunother Date: 2017-05-11 Impact factor: 3.452
Authors: Richard Stock; Tatjana Fischer; Katharina Aẞmus; Nadja Zoeller; Hanns Ackermann; Roland Kaufmann; Markus Meissner; Eva Valesky Journal: World Allergy Organ J Date: 2020-12-15 Impact factor: 4.084
Authors: Ali Selcuk; Abdullah Baysan; Sait Yesillik; Fevzi Demirel; Ozgur Kartal; Mustafa Gulec; Ugur Musabak; Osman Sener Journal: Ann Med Date: 2022-12 Impact factor: 5.348
Authors: Aida Abd El-Wahed; Nermeen Yosri; Hanem H Sakr; Ming Du; Ahmed F M Algethami; Chao Zhao; Ahmed H Abdelazeem; Haroon Elrasheid Tahir; Saad H D Masry; Mohamed M Abdel-Daim; Syed Ghulam Musharraf; Islam El-Garawani; Guoyin Kai; Yahya Al Naggar; Shaden A M Khalifa; Hesham R El-Seedi Journal: Toxins (Basel) Date: 2021-03-12 Impact factor: 4.546